On 2 November 2020, Kiadis and Sanofi announced that they reached agreement on a recommended public offer by Sanofi for the entire issued and outstanding share capital of Kiadis, for an offer price of EUR 5.45 (cum dividend) per Kiadis share.
-----
Earlier notes:
Friday, October 18, 2019
Kiadis Pharma intrinsic value oktober 2019. Not for the Graham Defensive Investor
Revenue = 0 EUR
Book value = EUR 50m Equity / 26m shares = EUR 2 per share (Twice what it was last year due to cash injection through private placement sale of new shares at EUR 9 per share)
The share price has fallen from EUR 12,20 (2018 below) to EUR 2,5 today. Just today down by 50% after bad news around one of the drugs under development.
Burning through cash quickly, less than 2 years on hand?
Conclusion: Even at this new lower price not a stock for the Graham Defensive Investor.
-------------------------------------------------
2018 back of the envelope math:
Book value = EUR 25m Equity / 20,1m shares = EUR 1 per share
Current share price: EUR 12,20
Price of private placement March 2018 (sale of shares to raise money for company) EUR 9,-
The company is developing something which could benefit the health of a lot of people and earn money for investors. How much that could be per share is outside my "circle of competence"
Current share price: EUR 12,20
Price of private placement March 2018 (sale of shares to raise money for company) EUR 9,-
The company is developing something which could benefit the health of a lot of people and earn money for investors. How much that could be per share is outside my "circle of competence"
No comments:
Post a Comment